prodchem
Aug 13, 2026
BASF's second-quarter 2026 results provide one of the clearest examples of how geopolitical disruption can rapidly reshape chemical-sector earnings.
BASF's net income reached €4.1 billion in Q2 2026, compared with just €79 million in the prior-year quarter. Chemical & Engineering News calculated the increase at approximately 167% on its earnings measure, placing BASF among the sharpest quarterly earnings improvements recorded by major chemical producers this year.
The improvement was not driven by one factor alone. Higher prices and volumes strengthened operating performance, while disruption surrounding the Middle East and the Strait of Hormuz contributed to tighter chemical-market conditions. At the same time, BASF's headline net income received a major one-time boost from its Coatings divestiture to Carlyle.
That combination makes BASF's quarter particularly useful for understanding the difference between operational earnings recovery and exceptional, event-driven profit gains.
BASF is one of the world's largest chemical producers, making its quarterly performance an important indicator for the broader industry.
The Q2 numbers demonstrate how quickly chemical earnings can change when:
Selling prices increase
Volumes recover
Feedstock markets tighten
Supply becomes constrained
Regional trade flows are disrupted
Portfolio changes generate exceptional gains
For chemical investors and procurement teams, the quarter provides a useful case study in how geopolitical events can influence the economics of global chemical supply chains.
BASF reported €4.1 billion of net income in Q2 2026, compared with €79 million in Q2 2025.
However, the headline figure requires careful interpretation.
The company recorded a €3.5 billion after-tax disposal gain from the sale of its Coatings business to Carlyle. That transaction closed on June 30, 2026.
Consequently, the majority of BASF's enormous net-income increase was related to the divestiture rather than recurring chemical operations.
The underlying operating picture was considerably stronger as well.
BASF generated €2.4 billion of EBITDA before special items in Q2, up €854 million from the prior-year quarter. The result significantly exceeded analyst expectations.
The improvement was driven primarily by stronger earnings in the Materials, Chemicals and Industrial Solutions businesses.
This makes the quarter more meaningful than the net-income number alone suggests.
BASF's Q2 sales reached approximately €17.2 billion, up 16% from €14.8 billion a year earlier.
The increase reflected:
11.5% higher prices
7.3% higher volumes
Negative currency effects
Negative portfolio effects
The combination of higher prices and volumes demonstrates that the earnings improvement had a substantial operating component.
The broader chemical industry experienced major supply-chain disruption associated with the Middle East conflict and difficulties around the Strait of Hormuz.
Chemical & Engineering News reported that producers across the US and Europe were able to raise selling prices as raw-material and energy costs increased, producing substantial earnings improvements for several major chemical companies.
BASF was one of the companies benefiting from these changed market conditions.
The Strait of Hormuz is particularly important for global energy and petrochemical flows.
Disruption can affect:
Crude oil
Refined products
Natural-gas-related supply
Petrochemical feedstocks
Shipping routes
Regional inventories
For chemical producers, changes in feedstock availability can quickly influence both production costs and selling prices.
BASF's Q2 sales increase was driven significantly by higher prices.
That is important because chemical producers often operate with substantial exposure to feedstock and energy costs.
When market prices rise faster than costs, producers can experience significant margin expansion.
That dynamic was visible across several major chemical companies during Q2.
Chemical & Engineering News' comparison of major chemical companies showed substantial Q2 earnings improvements across the industry.
Its table showed:
BASF earnings: +166.7%
Celanese: +71.3%
Evonik: +85.0%
LyondellBasell: +593.6%
Solvay: -35.4%
Arkema: +7.8%
The comparison demonstrates that BASF's improvement was significant, although not the largest percentage increase among major producers.
LyondellBasell's Q2 earnings increased by nearly 600% year over year according to C&EN's analysis.
That makes BASF's approximately 167% increase substantial, but not the most extreme war-linked earnings recovery in the sector.
This comparison is important when ranking BASF's performance objectively.
Featured Product
BASF's Chemicals segment benefited from stronger contribution margins during Q2.
The company's overall EBITDA-before-special-items improvement was primarily driven by higher earnings in several major operating segments, including Chemicals.
This suggests that the quarter's strength was not simply an accounting effect from the Carlyle transaction.
Materials was another major contributor to BASF's Q2 improvement.
The company specifically identified Materials, Chemicals and Industrial Solutions among the businesses that generated significant earnings increases.
These businesses are particularly exposed to global industrial demand and chemical pricing.
Industrial Solutions also contributed significantly to BASF's improved operating earnings.
The combination of better prices, volumes and contribution margins supported the segment's recovery.
This provides evidence that the improvement was relatively broad across BASF's portfolio.
Agricultural Solutions also recorded a slight earnings increase.
However, its pricing environment was less favorable than in several other BASF businesses.
BASF noted that prices declined in Agricultural Solutions and Nutrition & Care even as overall group prices increased.
Surface Technologies was one of the exceptions to BASF's broader earnings improvement.
The segment experienced significantly lower earnings, partly because of higher fixed costs.
That illustrates the uneven nature of the recovery across the company's portfolio.
This is perhaps the most important takeaway.
BASF's €4.1 billion net income is not representative of recurring quarterly profitability.
The €3.5 billion after-tax Coatings disposal gain accounted for most of the headline increase.
Investors evaluating the underlying business should therefore focus more heavily on:
EBITDA before special items
EBIT before special items
Segment margins
Operating cash flow
Free cash flow
BASF's Q2 free cash flow was approximately negative €0.2 billion, compared with positive €0.5 billion in Q2 2025.
This is an important counterpoint to the spectacular net-income figure.
The decline was primarily related to higher capital tied up as a result of higher raw-material prices.
In other words, the company's profit surge did not translate into stronger quarterly free cash flow.
BASF reported Q2 operating cash flow of approximately €524 million, around €1.1 billion below the prior-year quarter.
This further reinforces the distinction between:
reported profit growth and cash-generation improvement.
Higher raw-material prices can increase the amount of cash tied up in inventories and working capital.
That can create a situation where EBITDA rises while free cash flow weakens.
BASF's Q2 performance provides a clear example of this dynamic.
The Carlyle transaction was not simply a financial event.
It also represents BASF's broader portfolio transformation.
The company has been simplifying its portfolio while concentrating resources on businesses where it believes it can achieve stronger strategic positions and returns.
The completed Coatings transaction generated the large disposal gain but also removed an entire business from BASF's future operating portfolio.
That means future comparisons will need to account for the changed business mix.
A portion of BASF's historical revenue and earnings will no longer be directly comparable.
BASF continues implementing restructuring and cost-saving measures, particularly at its Ludwigshafen site.
Special charges in Q2 were primarily associated with restructuring measures and the implementation of new ERP systems.
The company is therefore simultaneously managing:
cyclical recovery + geopolitical volatility + structural restructuring.
BASF increased its 2026 adjusted EBITDA-before-special-items outlook to between €6.9 billion and €7.7 billion.
Previously, the company expected €6.2 billion–€7.0 billion.
The raised guidance suggests management expects the stronger operating environment to persist through at least part of the second half.
The company emphasized that the global economic environment remains highly uncertain.
The outlook depends significantly on developments surrounding:
The Middle East
The US-Iran situation
The Strait of Hormuz
Energy prices
Petrochemical feedstock availability
Global industrial production
BASF specifically noted that a prolonged Hormuz closure could weigh significantly on economic activity, while a rapid agreement could provide additional momentum.
C&EN's analysis highlights an important sector-wide issue: producers recognize that war-related supply tightness may not last.
When disruptions end and production normalizes, the chemical industry could once again face oversupply.
Evonik CEO Christian Kullmann described the earnings improvement as a temporary benefit rather than a fundamental change in the industry's structural challenges.
A better way to assess BASF's performance is to separate three components:
Higher prices, volumes and margins.
Tighter supply and disrupted trade flows.
The €3.5 billion after-tax Carlyle disposal gain.
Separating these elements provides a much clearer picture of the company's actual earnings trajectory.
Very High
Net income increased from €79 million to €4.1 billion, although the comparison was heavily distorted by the Coatings disposal.
Very High
At €2.4 billion, operating earnings significantly exceeded both the prior-year quarter and analyst expectations.
High
Sales increased 16%, supported by both higher prices and volumes.
High
Middle East disruption and Hormuz uncertainty materially affected global chemical-market conditions.
Medium
Q2 free cash flow remained negative at €0.2 billion, showing that stronger earnings did not automatically translate into stronger liquidity.
High
The Carlyle transaction represents a major change in BASF's portfolio and financial structure.
The most important indicators going forward include:
EBITDA before special items
Segment contribution margins
Chemical selling prices
Feedstock costs
Free cash flow
Working capital
Capital expenditure
Energy prices
Hormuz shipping conditions
Restructuring costs
Portfolio divestitures
Net debt
These metrics will help distinguish sustainable earnings improvement from temporary geopolitical benefits.
For chemical buyers, BASF's Q2 performance highlights the importance of monitoring both price and availability.
Procurement teams should track:
Feedstock costs
Regional supply disruptions
Shipping routes
Inventory levels
Contract pricing
Supplier production rates
Alternative sourcing options
A geopolitical event can change chemical economics far faster than traditional procurement cycles can adapt.
BASF's quarter illustrates the importance of maintaining flexibility during volatile markets.
Companies that can:
Adjust pricing
Manage inventories
Optimize production
Control costs
Diversify supply chains
Restructure efficiently
may be better positioned to capture temporary market opportunities without becoming overly dependent on them.
BASF's results also provide a broader read-through for European chemical producers.
Higher prices and tighter supply temporarily improved earnings for several companies.
But the structural challenges remain:
High European energy costs
Global overcapacity
Weak industrial demand
Regulatory pressure
Chinese competition
Geopolitical uncertainty
The earnings improvement should therefore not automatically be interpreted as a complete recovery of European chemical competitiveness.
BASF's Q2 2026 performance ranks among the year's most dramatic chemical-sector earnings improvements.
The company's €4.1 billion net income and approximately 167% earnings increase are striking, but the headline figure needs to be separated from the €3.5 billion after-tax gain from the Carlyle Coatings transaction.
The underlying operating recovery is nevertheless significant.
EBITDA before special items reached €2.4 billion, sales rose 16%, and higher prices and volumes improved performance across several major segments.
At the same time, negative Q2 free cash flow demonstrates why reported earnings alone are insufficient for evaluating the recovery.
The bigger question now is whether BASF can maintain stronger operating margins once Middle East-related supply disruptions ease.
If chemical markets normalize, the company could again face the structural pressures that affected the sector before the latest geopolitical shock.
For now, however, BASF's Q2 results provide a powerful benchmark for understanding how quickly geopolitical disruption can transform chemical-sector profitability.
BASF's Q2 2026 net income reached €4.1 billion, compared with €79 million a year earlier.
C&EN calculated the earnings increase at approximately 166.7%.
The headline profit was heavily boosted by a €3.5 billion after-tax gain from the Carlyle Coatings divestiture.
EBITDA before special items reached €2.4 billion, well above the prior-year quarter.
Sales increased 16% to €17.2 billion, driven primarily by higher prices and volumes.
Middle East disruption and Strait of Hormuz uncertainty contributed to tighter chemical-market conditions.
Q2 free cash flow was negative €0.2 billion, showing that profit growth did not translate directly into cash generation.
BASF raised its 2026 EBITDA-before-special-items outlook to €6.9 billion–€7.7 billion.
The earnings improvement should be assessed separately from the one-time divestiture gain.
Future results will show how much of the Q2 improvement remains after geopolitical supply disruptions normalize.
Found this useful?
Continue Reading
Tudriqev's approval rests on tumor response data rather than confirmed survival benefit, leaving the therapy under ongoing regulatory watch until Phase 3 trial results arrive in 2027. History shows that outcome is far from guaranteed, a factor worth weighing for anyone tied to its manufacturing supply chain.
TPC's polyisobutylene and C4 derivatives portfolio gives Eneos a strategic foothold in specialty petrochemicals in the US. The business adds a differentiated growth platform beyond traditional refining.
Explore how Replimune's Tudriqev overcame two FDA rejections to secure approval and why its unusual regulatory journey could become a benchmark for 2026 drug-development strategy.
